{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:33:30Z","timestamp":1789929210339,"version":"4.0.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T00:00:00Z","timestamp":1358208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1479-5876-11-16","type":"journal-article","created":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T15:43:58Z","timestamp":1358264638000},"source":"Crossref","is-referenced-by-count":44,"title":["Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC"],"prefix":"10.1186","volume":"11","author":[{"given":"Chandan","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M","family":"Eremin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Robins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard P","family":"Cowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A","family":"El-Sheemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibril A","family":"Jibril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Eremin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,15]]},"reference":[{"issue":"6832","key":"1468_CR1","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","volume":"410","author":"V Shankaran","year":"2001","unstructured":"Shankaran V: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001, 410 (6832): 1107-1111.","journal-title":"Nature"},{"issue":"6","key":"1468_CR2","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1084\/jem.20031981","volume":"199","author":"SE Street","year":"2004","unstructured":"Street SE: Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med. 2004, 199 (6): 879-884.","journal-title":"J Exp Med"},{"issue":"7101","key":"1468_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature04808","volume":"442","author":"JL Langowski","year":"2006","unstructured":"Langowski JL: IL-23 promotes tumour incidence and growth. Nature. 2006, 442 (7101): 461-465.","journal-title":"Nature"},{"key":"1468_CR4","first-page":"236","volume-title":"Essential immunology for surgeons","author":"M Aloysius","year":"2011","unstructured":"Aloysius M, Walker L, Eremin O: Cancer and the immune response, Ch 4. Essential immunology for surgeons. Edited by: Eremin O, Sewell H. 2011, Oxford: OUP, 236-300."},{"key":"1468_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD: The three Es of cancer immunoediting. Annu Rev Immunol. 2004, 22: 329-360.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"1468_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc1782","volume":"6","author":"KE de Visser","year":"2006","unstructured":"de Visser KE, Eichten A, Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006, 6 (1): 24-37.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"1468_CR7","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1172\/JCI28828","volume":"116","author":"G Gallina","year":"2006","unstructured":"Gallina G: Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest. 2006, 116 (10): 2777-2790.","journal-title":"J Clin Invest"},{"issue":"4","key":"1468_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V: Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012, 12 (4): 253-268.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"1468_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","volume":"22","author":"A Mantovani","year":"2010","unstructured":"Mantovani A, Sica A: Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010, 22 (2): 231-237.","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"1468_CR10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ijc.25429","volume":"127","author":"H Nishikawa","year":"2010","unstructured":"Nishikawa H, Sakaguchi S: Regulatory T cells in tumor immunity. Int J Cancer. 2010, 127 (4): 759-767.","journal-title":"Int J Cancer"},{"issue":"5","key":"1468_CR11","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.4049\/jimmunol.169.5.2756","volume":"169","author":"UK Liyanage","year":"2002","unstructured":"Liyanage UK: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002, 169 (5): 2756-2761.","journal-title":"J Immunol"},{"issue":"2","key":"1468_CR12","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.4049\/jimmunol.173.2.1444","volume":"173","author":"M Viguier","year":"2004","unstructured":"Viguier M: Foxp3 expressing CD4\u2009+\u2009CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004, 173 (2): 1444-1453.","journal-title":"J Immunol"},{"issue":"1","key":"1468_CR13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jss.2004.10.004","volume":"124","author":"H Kawaida","year":"2005","unstructured":"Kawaida H: Distribution of CD4\u2009+\u2009CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res. 2005, 124 (1): 151-157.","journal-title":"J Surg Res"},{"issue":"10","key":"1468_CR14","doi-asserted-by":"publisher","first-page":"7398","DOI":"10.4049\/jimmunol.177.10.7398","volume":"177","author":"AM Miller","year":"2006","unstructured":"Miller AM: CD4\u2009+\u2009CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol. 2006, 177 (10): 7398-7405.","journal-title":"J Immunol"},{"issue":"3","key":"1468_CR15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1021\/mp1004228","volume":"8","author":"EA Vasievich","year":"2011","unstructured":"Vasievich EA, Huang L: The suppressive tumor microenvironment: a challenge in cancer immunotherapy. Mol Pharm. 2011, 8 (3): 635-641.","journal-title":"Mol Pharm"},{"issue":"9","key":"1468_CR16","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004, 10 (9): 942-949.","journal-title":"Nat Med"},{"issue":"6","key":"1468_CR17","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1084\/jem.183.6.2541","volume":"183","author":"TL Walunas","year":"1996","unstructured":"Walunas TL, Bakker CY, Bluestone JA: CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med. 1996, 183 (6): 2541-2550.","journal-title":"J Exp Med"},{"issue":"2","key":"1468_CR18","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/1521-4141(200202)32:2<366::AID-IMMU366>3.0.CO;2-5","volume":"32","author":"RJ Greenwald","year":"2002","unstructured":"Greenwald RJ: CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol. 2002, 32 (2): 366-373.","journal-title":"Eur J Immunol"},{"issue":"3\u20134","key":"1468_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10555-007-9072-0","volume":"26","author":"JE Talmadge","year":"2007","unstructured":"Talmadge JE, Donkor M, Scholar E: Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 2007, 26 (3\u20134): 373-400.","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"1468_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.coi.2010.01.021","volume":"22","author":"E Peranzoni","year":"2010","unstructured":"Peranzoni E: Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 2010, 22 (2): 238-244.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"1468_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cytogfr.2009.11.008","volume":"21","author":"B Bierie","year":"2010","unstructured":"Bierie B, Moses HL: Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev. 2010, 21 (1): 49-59.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"1468_CR22","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1158\/0008-5472.CAN-05-1299","volume":"66","author":"B Huang","year":"2006","unstructured":"Huang B: Gr-1\u2009+\u2009CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006, 66 (2): 1123-1131.","journal-title":"Cancer Res"},{"issue":"1","key":"1468_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel L: Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008, 8 (1): 59-73.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1468_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","volume":"102","author":"WM Liu","year":"2010","unstructured":"Liu WM: Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2010, 102 (1): 115-123.","journal-title":"Br J Cancer"},{"key":"1468_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/med\/9780199586875.003.0129","volume-title":"Essential Immunology for Surgeons","author":"M Aloysius","year":"2011","unstructured":"Aloysius M, Verma C, Eremin O: Therapy and Host Defences Ch 7. Essential Immunology for Surgeons. Edited by: Eremin O, Sewell H. 2011, Oxford: OUP, 379-402."},{"issue":"12","key":"1468_CR26","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-09-2891","volume":"16","author":"L Zitvogel","year":"2010","unstructured":"Zitvogel L: Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010, 16 (12): 3100-3104.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1468_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/sj.bjc.6600347","volume":"87","author":"N Tsavaris","year":"2002","unstructured":"Tsavaris N: Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 2002, 87 (1): 21-27.","journal-title":"Br J Cancer"},{"issue":"3","key":"1468_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cyto.2003.10.004","volume":"25","author":"L Pusztai","year":"2004","unstructured":"Pusztai L: Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004, 25 (3): 94-102.","journal-title":"Cytokine"},{"issue":"2","key":"1468_CR29","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/eji.200324181","volume":"34","author":"F Ghiringhelli","year":"2004","unstructured":"Ghiringhelli F: CD4\u2009+\u2009CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004, 34 (2): 336-344.","journal-title":"Eur J Immunol"},{"issue":"7","key":"1468_CR30","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","volume":"105","author":"ME Lutsiak","year":"2005","unstructured":"Lutsiak ME: Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005, 105 (7): 2862-2868.","journal-title":"Blood"},{"issue":"6","key":"1468_CR31","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1200\/JCO.20.6.1456","volume":"20","author":"IC Smith","year":"2002","unstructured":"Smith IC: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002, 20 (6): 1456-1466.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1468_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/1471-2407-11-179","volume":"18","author":"L Walker","year":"2011","unstructured":"Walker L: Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer. BMC Cancer. 2011, 18 (11): 179-","journal-title":"BMC Cancer"},{"issue":"3","key":"1468_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00262-008-0576-4","volume":"58","author":"CN Baxevanis","year":"2009","unstructured":"Baxevanis CN, Perez SA, Papamichail M: Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother. 2009, 58 (3): 317-324.","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"1468_CR34","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1158\/0008-5472.CAN-06-4174","volume":"67","author":"P Sinha","year":"2007","unstructured":"Sinha P: Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007, 67 (9): 4507-4513.","journal-title":"Cancer Res"},{"issue":"1","key":"1468_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","volume":"58","author":"CM Diaz-Montero","year":"2009","unstructured":"Diaz-Montero CM: Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009, 58 (1): 49-59.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"1468_CR36","first-page":"273","volume":"22","author":"T Aruga","year":"2009","unstructured":"Aruga T: A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncol Rep. 2009, 22 (2): 273-278.","journal-title":"Oncol Rep"},{"issue":"4","key":"1468_CR37","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s12253-010-9256-8","volume":"16","author":"M Jaberipour","year":"2010","unstructured":"Jaberipour M: Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathol Oncol Res. 2010, 16 (4): 547-551.","journal-title":"Pathol Oncol Res"},{"issue":"4","key":"1468_CR38","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00262-009-0780-x","volume":"59","author":"AJ Rech","year":"2010","unstructured":"Rech AJ: Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunol Immunother. 2010, 59 (4): 599-607.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"1468_CR39","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1365-2249.2007.03521.x","volume":"150","author":"S Audia","year":"2007","unstructured":"Audia S: Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol. 2007, 150 (3): 523-530.","journal-title":"Clin Exp Immunol"},{"key":"1468_CR40","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/1471-2407-9-231","volume":"9","author":"AS Mansfield","year":"2009","unstructured":"Mansfield AS: Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer. 2009, 9: 231-","journal-title":"BMC Cancer"},{"issue":"2","key":"1468_CR41","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10549-011-1647-3","volume":"130","author":"F Liu","year":"2011","unstructured":"Liu F: CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011, 130 (2): 645-655.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1468_CR42","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/jso.21446","volume":"101","author":"SV Liu","year":"2010","unstructured":"Liu SV: Neoadjuvant therapy for breast cancer. J Surg Oncol. 2010, 101 (4): 283-291.","journal-title":"J Surg Oncol"},{"issue":"8","key":"1468_CR43","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1158\/1078-0432.CCR-07-4491","volume":"14","author":"S Ladoire","year":"2008","unstructured":"Ladoire S: Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res. 2008, 14 (8): 2413-2420.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1468_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10549-012-2245-8","volume":"136","author":"N Oda","year":"2012","unstructured":"Oda N, Shimazu K: Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU\/epirubicin\/cyclophosphamide in breast cancer patients. Breast Cancer Res Treat. 2012, 136 (1): 107-116.","journal-title":"Breast Cancer Res Treat"},{"issue":"34","key":"1468_CR45","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","volume":"24","author":"GJ Bates","year":"2006","unstructured":"Bates GJ, Fox SB: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006, 24 (34): 5373-5380.","journal-title":"J Clin Oncol"},{"key":"1468_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2407-8-57","volume":"8","author":"H Ghebeh","year":"2008","unstructured":"Ghebeh H, Barhoush E: FOXP3+ Tregs and B7-H1+\/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer. 2008, 8: 5-","journal-title":"BMC Cancer"},{"issue":"11","key":"1468_CR47","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1200\/JCO.2008.17.9036","volume":"27","author":"A Merlo","year":"2009","unstructured":"Merlo A, Casalini P: FOXP3 expression and overall survival in breast cancer. J Clin Oncol. 2009, 27 (11): 1746-1752.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1468_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3109\/0284186X.2012.731520","volume":"52","author":"S Lee","year":"2013","unstructured":"Lee S, Cho EY: Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncol. 2013, 52 (1): 73-8149.","journal-title":"Acta Oncol"},{"issue":"1","key":"1468_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00432-009-0634-0","volume":"136","author":"CY Liu","year":"2010","unstructured":"Liu CY: Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+\/CD14(\u2212)\/CD15+\/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010, 136 (1): 35-45.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"24","key":"1468_CR50","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.1182\/blood-2010-11-317321","volume":"117","author":"B Hoechst","year":"2011","unstructured":"Hoechst B: Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood. 2011, 117 (24): 6532-6541.","journal-title":"Blood"},{"issue":"4","key":"1468_CR51","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/bcr1746","volume":"9","author":"DG DeNardo","year":"2007","unstructured":"DeNardo DG, Coussens LM: Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007, 9 (4): 212-","journal-title":"Breast Cancer Res"},{"issue":"7","key":"1468_CR52","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00262-010-0849-6","volume":"59","author":"Y Ji","year":"2010","unstructured":"Ji Y, Zhang W: Th17 cells: positive or negative role in tumor?. Cancer Immunol Immunother. 2010, 59 (7): 979-987.","journal-title":"Cancer Immunol Immunother"},{"issue":"104","key":"1468_CR53","doi-asserted-by":"publisher","first-page":"104ra100","DOI":"10.1126\/scitranslmed.3002949","volume":"3","author":"I Kryczek","year":"2011","unstructured":"Kryczek I: Human TH17 cells are long-lived effector memory cells. Sci Transl Med. 2011, 3 (104): 104ra100-","journal-title":"Sci Transl Med"},{"issue":"2","key":"1468_CR54","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1182\/blood-2007-11-120998","volume":"112","author":"P Muranski","year":"2008","unstructured":"Muranski P: Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008, 112 (2): 362-373.","journal-title":"Blood"},{"issue":"5","key":"1468_CR55","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.immuni.2009.09.014","volume":"31","author":"N Martin-Orozco","year":"2009","unstructured":"Martin-Orozco N: T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009, 31 (5): 787-798.","journal-title":"Immunity"},{"issue":"1","key":"1468_CR56","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12013-011-9276-3","volume":"62","author":"L Yang","year":"2012","unstructured":"Yang L: Expression of Th17 cells in breast cancer tissue and its association with clinical parameters. Cell Biochem Biophys. 2012, 62 (1): 153-159.","journal-title":"Cell Biochem Biophys"},{"issue":"3","key":"1468_CR57","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1158\/0008-5472.CAN-10-1259","volume":"71","author":"S Viaud","year":"2011","unstructured":"Viaud S: Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res. 2011, 71 (3): 661-665.","journal-title":"Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-11-16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1479-5876-11-16\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-11-16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T19:01:50Z","timestamp":1714849310000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-11-16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,15]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1468"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-11-16","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,15]]},"article-number":"16"}}